Welcome to our dedicated page for Immunic SEC filings (Ticker: IMUX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immunic, Inc. (IMUX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. As a Nasdaq-listed biotechnology issuer, Immunic uses filings such as Forms 10-K, 10-Q, and 8-K to report on its financial condition, clinical development progress, capital structure, and material corporate events.
Current reports on Form 8-K are particularly relevant for tracking Immunic’s milestones. Recent 8-K filings reference press releases on quarterly financial results and corporate updates, including spending on research and development for vidofludimus calcium (IMU-838) and other programs, as well as financings such as registered direct offerings and underwritten public offerings. Other 8-Ks describe presentation of new multiple sclerosis data at major scientific meetings and provide details on items like stock appreciation rights grants and Nasdaq listing notices regarding minimum bid price requirements.
Investors can also use SEC filings to monitor liquidity and risk disclosures, where Immunic discusses its cash and cash equivalents, the need to raise additional capital to fund operations, and the implications of financing structures. Filings may further elaborate on the company’s intellectual property strategy for vidofludimus calcium and other pipeline assets, complementing information in press releases.
On Stock Titan, these documents are supplemented with AI-powered summaries that explain key points in accessible language, helping readers quickly understand the significance of lengthy filings. Real-time updates from EDGAR ensure that new IMUX filings, including 10-Q and 10-K reports and any Form 4 insider transaction disclosures when available, are added promptly so users can review changes in ownership, compensation-related grants, and other governance matters alongside Immunic’s clinical and financial reporting.
Immunic, Inc. appointed Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer effective April 24, 2026, succeeding co-founder Andreas Muehler, M.D., M.B.A., who resigned as CMO and will transition to a consulting role.
Dr. Panzara brings more than 25 years of neurology drug development experience from Neurvati, Wave Life Sciences, Sanofi Genzyme and Biogen, including work on several approved multiple sclerosis therapies. His employment terms include a $600,000 annual base salary, a target bonus of at least 50% of base salary, a $125,000 signing bonus and stock options to purchase 300,000 shares that vest over three years. Dr. Muehler will receive 12 months of base-salary severance from both Immunic and Immunic AG, full vesting of outstanding equity awards and a 10‑month consulting arrangement at $10,000 per month.
Immunic, Inc. is implementing a 1-for-10 reverse stock split of its common stock, effective as of 12:01 a.m. Eastern Time on April 27, 2026. Every 10 existing shares will be combined into 1 new share, reducing issued and outstanding shares from approximately 136 million to approximately 13.6 million, without changing the number of authorized shares or par value.
The split is intended primarily to allow Immunic to meet contractual obligations under a securities purchase agreement dated February 12, 2026. All stock options, warrants, restricted stock units and similar securities will be proportionally adjusted in share number and exercise price. No fractional shares will be issued; instead, the transfer agent will aggregate fractional interests, sell the resulting whole shares on the open market and distribute each stockholder’s cash share of the proceeds. Trading on the Nasdaq Capital Market under the symbol IMUX will continue, using a new CUSIP number 4525EP200 for the split-adjusted stock starting April 27, 2026.
Immunic, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add detailed Part III information on directors, executive officers, compensation and ownership that was previously omitted.
The filing also describes a 1-for-10 reverse stock split of common stock, approved by stockholders on April 14, 2026 and implemented by a charter amendment effective April 27, 2026. As of April 16, 2026, Immunic had 136,214,825 common shares outstanding and a non‑affiliate equity market value of $83.1 million based on the June 30, 2025 Nasdaq closing price.
The board has nine members, seven of whom are deemed independent under Nasdaq rules, and operates audit, compensation, and nominating and governance committees. The amendment outlines director retainers, stock option grants, 2025 executive pay, severance and change‑in‑control protections, equity plans and major institutional shareholders.
Immunic, Inc. ownership disclosure: Avidity Partners-related entities and Michael Gregory report shared beneficial ownership of 13,958,410 shares of Immunic common stock, representing 9.9% of the class.
The filing is a joint Schedule 13G listing the reporting persons, their Delaware/Cayman jurisdictions, shared voting and dispositive power over the same 13,958,410 shares, and a joint filing agreement. The signatures indicate Michael Gregory as managing member. The filing contains a disclaimer of beneficial ownership by each reporting person except for pecuniary interest.
Immunic, Inc. reported that stockholders approved a proposal authorizing its board to implement a reverse stock split of common stock at a ratio between 1-for-10 and 1-for-30. Of 130,464,825 shares outstanding on the record date, 70,622,667 shares, or about 54.1%, were represented at the special meeting.
Stockholders supported the proposal with 57,404,749 votes for, 12,594,555 against, and 623,363 abstentions. Following this approval, the board chose a 1-for-10 reverse stock split, expected to become effective at 12:01 a.m. Eastern Time on April 27, 2026, with the post-split shares trading on the Nasdaq Capital Market under the IMUX symbol.
Immunic, Inc. has signed a Retention Bonus Agreement with Chief Executive Officer Daniel Vitt as it begins a search for a new CEO. If he remains employed through the ninety-first day after a new CEO is hired, he will receive a $670,000 cash retention bonus.
The bonus is generally payable in a lump sum after this retention date, or within five days if Immunic terminates him without Cause or he resigns for Good Reason before then. Any bonus paid will be credited against future cash severance, and both parties agreed to mutual non-disparagement under New York law.
Immunic, Inc. is registering up to 458,152,000 shares of common stock for resale by selling stockholders, consisting of up to 229,076,000 Pre-Funded Warrant Shares and up to 229,076,000 Common Warrant Shares. The company is not selling any shares and will receive proceeds only if Warrants are exercised for cash.
The Resale Shares equal approximately 67% of outstanding common stock on a pre-split basis. The company plans a stockholder vote on a reverse split (1-for-10 to 1-for-30) and intends to effect the Reverse Stock Split prior to the registration statement’s effectiveness. The private placement closed on February 17, 2026 and generated gross proceeds of $200.0M.
Immunic, Inc. announced that it has regained compliance with Nasdaq’s Minimum Bid Price Requirement for continued listing on The Nasdaq Capital Market. Nasdaq confirmed that the company’s common stock closed at or above $1.00 per share for 20 consecutive business days from February 27, 2026 to March 26, 2026, and the matter is now closed.
The company is a late-stage biotechnology business focused on novel oral therapies for neurologic diseases. Its lead candidate, vidofludimus calcium (IMU-838), is in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, and is supported by earlier phase 2 results in multiple sclerosis and other conditions.
IMMUNIC, INC. has filed an initial Form 3 ownership report for director Jon Congleton. This filing identifies him as a board member but shows no reported transactions or derivative positions in the data provided. It is a routine regulatory disclosure about insider status.
Immunic, Inc. has appointed veteran biopharmaceutical executive Jon Congleton to its board of directors, effective March 27, 2026, as a Class II director with a term running until the 2028 annual meeting. He will also chair the board’s Compensation Committee, adding extensive CNS and multiple sclerosis commercialization experience to the company’s governance.
In connection with his appointment, Congleton received stock options to purchase 500,000 shares of common stock, vesting monthly over three years at an exercise price equal to the March 27, 2026 Nasdaq closing price, subject to shareholder approval of an increase in shares reserved under Immunic’s 2019 Omnibus Equity Incentive Plan. The board size increased from eight to nine directors. Immunic highlights Congleton’s nearly 40-year biopharma background and notes its lead MS asset, vidofludimus calcium, is in phase 3 trials with top-line data expected by the end of 2026.